MCID: CHR066
MIFTS: 68

Chronic Fatigue Syndrome

Categories: Immune diseases, Neuronal diseases, Rare diseases

Aliases & Classifications for Chronic Fatigue Syndrome

MalaCards integrated aliases for Chronic Fatigue Syndrome:

Name: Chronic Fatigue Syndrome 12 77 54 56 44 3 15 17 74
Myalgic Encephalomyelitis 12 77 54
Cfs 12 15
Chronic Fatigue Immune Dysfunction Syndrome 54
Systemic Exertion Intolerance Disease 54
Postviral Fatigue Syndrome 12
Encephalomyelitis, Myalgic 77
Fatigue Syndrome, Chronic 45
Myalgic Encephalitis 12
Chronic Fatigue 6

Classifications:



External Ids:

Disease Ontology 12 DOID:8544
ICD9CM 36 780.71
MeSH 45 D015673
NCIt 51 C3037
SNOMED-CT 69 51771007 52702003
ICD10 34 G93.3 R53.82
UMLS 74 C0015674

Summaries for Chronic Fatigue Syndrome

MedlinePlus : 44 What is chronic fatigue syndrome? Chronic fatigue syndrome (CFS) is a serious, long-term illness that affects many body systems. Another name for it is myalgic encephalomyelitis/chronic fatigue syndrome (ME/CFS). CFS can often make you unable to do your usual activities. Sometimes you may not even be able to get out of bed. What causes chronic fatigue syndrome? Scientists don't know what causes CFS. There may be more than one thing that causes it. It is possible that two or more triggers might work together to cause the illness. Who is at risk for chronic fatigue syndrome? Anyone can get CFS, but it is most common in people between 40 and 60 years old. Adult women have it more often that adult men. Whites are more likely than other races to get a diagnosis of CFS, but many people with CFS have not been diagnosed with it. What are the symptoms of chronic fatigue syndrome? CFS symptoms can include Severe fatigue that is not improved by rest Sleep problems Post-exertional malaise (PEM), where your symptoms get worse after any physical or mental activity Problems with thinking and concentrating Pain Dizziness CFS can be unpredictable. Your symptoms may come and go. They may change over time - sometimes they might get better, and other times they may get worse. How is chronic fatigue syndrome diagnosed? CFS can be difficult to diagnose. There are no tests for it, and other illnesses can cause similar symptoms. Your health care provider has to rule out other diseases before making a diagnosis of CFS. He or she will do a thorough medical exam, including Asking about your medical history and your family's medical history Asking about your current illness, including your symptoms. Your doctor will want to know how often you have symptoms, how bad they are, how long they have lasted, and how they affect your life. A thorough physical and mental status exam Blood, urine or other tests What are the treatments for chronic fatigue syndrome? There is no cure or approved treatment for CFS, but you may be able to treat or manage some of your symptoms. You, your family, and your health care provider should work together to decide on a plan. You should figure out which symptom causes the most problems, and try to treat that first. For example, if sleep problems affect you the most, you might first try using good sleep habits. If those do not help, you may need to take medicines or see a sleep specialist. Strategies such as learning new ways to manage activity can also be helpful. You need to make sure that you do not "push and crash." This can happen when you feel better, do too much, and then get worse again. Since the process of developing a treatment plan and attending to self-care can be hard if you have CFS, it is important to have support from family members and friends. Don't try any new treatments without talking to your health care provider. Some treatments that are promoted as cures for CFS are unproven, often costly, and could be dangerous. Centers for Disease Control and Prevention

MalaCards based summary : Chronic Fatigue Syndrome, also known as myalgic encephalomyelitis, is related to pain - chronic and irritable bowel syndrome, and has symptoms including muscle weakness, fever and fatigue. An important gene associated with Chronic Fatigue Syndrome is RNASEL (Ribonuclease L), and among its related pathways/superpathways are Innate Immune System and TGF-Beta Pathway. The drugs Sodium oxybate and Dinoprostone have been mentioned in the context of this disorder. Affiliated tissues include testes, brain and pituitary, and related phenotypes are Synthetic lethal with MLN4924 (a NAE inhibitor) and Synthetic lethal with MLN4924 (a NAE inhibitor)

Disease Ontology : 12 A syndrome that involves prolonged and severe tiredness or weariness that is unrelated to exertion, is not relieved by rest and for a minimum of six months and is not directly caused by other conditions.

NIH Rare Diseases : 54 Chronic fatigue syndrome, also known as systemic exertion intolerance disease, is a condition that causes extreme, long-lasting fatigue which can limit the ability to participate in ordinary, daily activities. It generally occurs in young adults (20 to 40 years of age) and is twice as common in women. The main symptom is disabling fatigue that does not improve with rest. Other signs and symptoms may include muscle pain, joint pain, concentration and memory problems, headaches, sleep problems, fever, sore throat, and/or tender lymph nodes. The exact cause is not known. There is still no cure or effective treatment for this condition but there are several clinical trials. There is debate in the medical literature about the relationship between myalgic encephalomyelitis and chronic fatigue syndrome. There is no consensus on nomenclature or classification for these disorders. Different countries, organizations, and researchers continue to use different names to describe these conditions.

CDC : 3 Myalgic encephalomyelitis/chronic fatigue syndrome (ME/CFS) is a serious, long-term illness that affects many body systems. People with ME/CFS are often not able to do their usual activities. At times, ME/CFS may confine them to bed. People with ME/CFS have severe fatigue and sleep problems. ME/CFS may get worse after people with the illness try to do as much as they want or need to do. This symptom is known as post-exertional malaise (PEM). Other symptoms can include problems with thinking and concentrating, pain, and dizziness.

Wikipedia : 77 Chronic fatigue syndrome (CFS), also referred to as myalgic encephalomyelitis (ME), is a medical... more...

Related Diseases for Chronic Fatigue Syndrome

Diseases related to Chronic Fatigue Syndrome via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 574)
# Related Disease Score Top Affiliating Genes
1 pain - chronic 32.8 COMT NR3C1
2 irritable bowel syndrome 32.0 CRH IL10 SLC6A4 TNF
3 fibromyalgia 31.5 COMT CRH IGF1 IL6 SLC6A4
4 depression 30.8 CRH HTR1A MAOA NR3C1 SLC6A4 TPH2
5 personality disorder 30.6 COMT HTR1A MAOA SLC6A4
6 brucellosis 30.6 CXCL8 IL10 IL2 IL6 TNF
7 alexithymia 30.5 COMT HTR1A SLC6A4
8 multiple sclerosis 30.5 IL10 IL1B IL2 IL6 TNF
9 lyme disease 30.3 IL1B IL6 TNF
10 disease of mental health 30.1 COMT CRH HTR1A IL6 MAOA POMC
11 juvenile rheumatoid arthritis 30.1 IL1B IL6 TNF
12 atypical depressive disorder 30.1 CRH MAOA SLC6A4
13 generalized anxiety disorder 30.1 COMT HTR1A MAOA SLC6A4
14 anxiety 30.0 COMT CRH HTR1A MAOA NR3C1 SLC6A4
15 anorexia nervosa 30.0 COMT CRH IGF1 POMC SLC6A4
16 eating disorder 30.0 COMT CRH POMC SLC6A4
17 joint disorders 30.0 IL1B IL6 TNF
18 attention deficit-hyperactivity disorder 29.9 COMT HTR1A MAOA SLC6A4 TPH2
19 q fever 29.9 IL10 IL1B IL6 TNF
20 dyspepsia 29.9 CXCL8 HTR1A SLC6A4
21 post-traumatic stress disorder 29.8 COMT CRH IL1B MAOA NR3C1 SLC6A4
22 traumatic brain injury 29.8 COMT IGF1 IL10 IL6
23 brain injury 29.8 COMT IGF1 IL10 IL6
24 arteries, anomalies of 29.8 IL1B IL6 TNF
25 typhoid fever 29.7 IL1B IL6 TNF
26 migraine with or without aura 1 29.7 COMT HTR1A MAOA SLC6A4 TNF
27 chronic active epstein-barr virus infection 29.7 IL10 IL2 TGFB1
28 chikungunya 29.7 IL1B IL6 TNF
29 sarcoidosis 1 29.7 IL1B IL2 TNF
30 burns 29.6 CRH IL1B TNF
31 lung disease 29.6 CXCL8 IL10 IL1B IL6 TGFB1 TNF
32 cystitis 29.6 CXCL8 IL6 TNF
33 paracoccidioidomycosis 29.5 IL10 IL2 IL6 TNF
34 complex regional pain syndrome 29.5 IL10 IL1B IL6 TNF
35 osteoarthritis 29.4 IL1B IL6 TGFB1 TNF
36 borderline personality disorder 29.4 COMT HTR1A MAOA NR3C1 SLC6A4 TPH2
37 obsessive-compulsive disorder 29.3 COMT CRH HTR1A MAOA SLC6A4 TPH2
38 autoimmune disease 29.3 IL10 IL1B IL2 IL6 TNF
39 endogenous depression 29.3 CRH HTR1A IL1B IL2 MAOA NR3C1
40 acquired immunodeficiency syndrome 29.3 IL10 IL1B IL2 IL6 TNF
41 arthritis 29.2 CXCL8 IL10 IL1B IL6 TGFB1 TNF
42 chlamydia 29.1 CXCL8 IL10 IL1B IL6 TNF
43 sleep apnea 29.1 CXCL8 IGF1 IL1B IL6 TNF
44 systemic lupus erythematosus 29.0 IL10 IL1B IL2 IL6 TGFB1 TNF
45 pneumonia 29.0 CXCL8 IL10 IL1B IL6 TNF
46 gastroenteritis 29.0 CXCL8 IL10 IL1B IL6 TNF
47 rheumatoid arthritis 28.9 CXCL8 IL10 IL1B IL2 IL6 TGFB1
48 mood disorder 28.8 COMT CRH HTR1A IL6 MAOA NR3C1
49 spinal cord injury 28.8 CXCL8 IL6 TGFB1 TNF
50 colitis 28.8 CXCL8 IL10 IL1B IL2 IL6 TNF

Graphical network of the top 20 diseases related to Chronic Fatigue Syndrome:



Diseases related to Chronic Fatigue Syndrome

Symptoms & Phenotypes for Chronic Fatigue Syndrome

UMLS symptoms related to Chronic Fatigue Syndrome:


muscle weakness, fever, fatigue, pruritus, back pain, myalgia, sciatica, muscle cramp, muscle rigidity, muscle spasticity, (non-specific) malaise and fatigue, other malaise and fatigue

GenomeRNAi Phenotypes related to Chronic Fatigue Syndrome according to GeneCards Suite gene sharing:

27
# Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Synthetic lethal with MLN4924 (a NAE inhibitor) GR00250-A-1 9.77 CXCL8 EIF2AK2 IL10 IL1B IL2 TGFB1
2 Synthetic lethal with MLN4924 (a NAE inhibitor) GR00250-A-2 9.77 CXCL8 EIF2AK2 IL10 IL1B IL2 TGFB1
3 Decreased viability with paclitaxel GR00179-A-1 9.55 IGF1 IL10 TGFB1
4 Decreased viability with paclitaxel GR00179-A-2 9.55 IGF1
5 Decreased viability with paclitaxel GR00179-A-3 9.55 TGFB1
6 Reduced mammosphere formation GR00396-S 9.5 CXCL8 EIF2AK2 IGF1 MAOA NR3C1 POMC

MGI Mouse Phenotypes related to Chronic Fatigue Syndrome:

47 (show all 19)
# Description MGI Source Accession Score Top Affiliating Genes
1 behavior/neurological MP:0005386 10.45 COMT CRH HTR1A IL10 IL2 IL6
2 cardiovascular system MP:0005385 10.41 COMT HTR1A IGF1 IL10 IL1B IL2
3 homeostasis/metabolism MP:0005376 10.41 COMT CRH HTR1A IGF1 IL10 IL1B
4 growth/size/body region MP:0005378 10.35 CRH IGF1 IL10 IL1B IL2 IL6
5 cellular MP:0005384 10.34 CRH EIF2AK2 IGF1 IL10 IL2 IL6
6 hematopoietic system MP:0005397 10.34 COMT CRH EIF2AK2 IGF1 IL10 IL1B
7 endocrine/exocrine gland MP:0005379 10.33 COMT CRH IGF1 IL10 IL2 IL6
8 immune system MP:0005387 10.31 COMT CRH EIF2AK2 IGF1 IL10 IL1B
9 mortality/aging MP:0010768 10.28 EIF2AK2 HTR1A IGF1 IL10 IL1B IL2
10 integument MP:0010771 10.26 CRH IGF1 IL10 IL1B IL6 NR3C1
11 nervous system MP:0003631 10.22 COMT CRH HTR1A IGF1 IL10 IL1B
12 adipose tissue MP:0005375 10.19 CRH IGF1 IL6 NR3C1 POMC TGFB1
13 liver/biliary system MP:0005370 10.06 CRH IL10 IL2 IL6 NR3C1 POMC
14 neoplasm MP:0002006 10.02 EIF2AK2 IGF1 IL10 IL1B IL2 IL6
15 muscle MP:0005369 10.01 IGF1 IL10 IL6 NR3C1 SLC6A4 SUN2
16 no phenotypic analysis MP:0003012 9.86 CRH HTR1A IL10 IL2 NR3C1 POMC
17 renal/urinary system MP:0005367 9.7 COMT CRH IGF1 IL6 NR3C1 POMC
18 reproductive system MP:0005389 9.61 COMT IGF1 IL10 IL2 IL6 NR3C1
19 respiratory system MP:0005388 9.32 COMT CRH IGF1 IL10 IL2 IL6

Drugs & Therapeutics for Chronic Fatigue Syndrome

Drugs for Chronic Fatigue Syndrome (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 179)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Sodium oxybate Approved Phase 4 502-85-2 5360545
2
Dinoprostone Approved Phase 4 363-24-6 5280360
3
Dopamine Approved Phase 4,Phase 2,Phase 3 62-31-7, 51-61-6 681
4
Sodium Citrate Approved, Investigational Phase 4 68-04-2
5
Iron Approved, Experimental Phase 4 7439-89-6, 15438-31-0 27284 23925
6
tannic acid Approved Phase 4 1401-55-4
7
Benzocaine Approved, Investigational Phase 4 1994-09-7, 94-09-7 2337
8
Calcium Approved, Nutraceutical Phase 4 7440-70-2 271
9
Vitamin D Approved, Nutraceutical, Vet_approved Phase 4 1406-16-2
10
Ergocalciferol Approved, Nutraceutical Phase 4 50-14-6 5280793
11
Citric Acid Approved, Nutraceutical, Vet_approved Phase 4 77-92-9 311
12 Central Nervous System Depressants Phase 4,Phase 2,Not Applicable
13 Anesthetics Phase 4,Phase 2,Phase 1,Not Applicable
14 Anesthetics, Intravenous Phase 4
15 Adjuvants, Anesthesia Phase 4,Phase 1
16 Anesthetics, General Phase 4
17 Calcium, Dietary Phase 4
18 Micronutrients Phase 4,Phase 2,Phase 3,Not Applicable
19 Vitamins Phase 4,Phase 2,Phase 3,Not Applicable
20 Trace Elements Phase 4,Phase 2,Phase 3,Not Applicable
21 Hormones Phase 4,Phase 1,Phase 2
22 Nutrients Phase 4,Phase 2,Phase 3,Not Applicable
23 Ergocalciferols Phase 4
24 Vitamin D2 Phase 4
25 Calciferol Phase 4
26 Bone Density Conservation Agents Phase 4
27 Central Nervous System Stimulants Phase 4,Phase 2
28 Dopamine Uptake Inhibitors Phase 4,Phase 2
29 Neurotransmitter Agents Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable
30 Neurotransmitter Uptake Inhibitors Phase 4,Phase 2,Phase 3,Not Applicable
31 Dopamine Agents Phase 4,Phase 2,Phase 3
32 Lisdexamfetamine Dimesylate Phase 4
33 Vasodilator Agents Phase 4,Phase 1
34 Sildenafil Citrate Phase 4 171599-83-0
35 Phosphodiesterase 5 Inhibitors Phase 4
36 Citrate Phase 4
37 Phosphodiesterase Inhibitors Phase 4
38 Pharmaceutical Solutions Phase 4,Phase 3,Phase 1
39 Hematinics Phase 4
40 Ferric Compounds Phase 4
41
rituximab Approved Phase 3,Phase 2 174722-31-7 10201696
42
Norepinephrine Approved Phase 2, Phase 3,Phase 3,Not Applicable 51-41-2 439260
43
Vitamin C Approved, Nutraceutical Phase 2, Phase 3,Phase 3,Not Applicable 50-81-7 54670067 5785
44
Coenzyme Q10 Approved, Investigational, Nutraceutical Phase 2, Phase 3,Not Applicable 303-98-0 5281915
45
Serine Approved, Nutraceutical Phase 2, Phase 3,Not Applicable 56-45-1 5951
46 Antibodies Phase 3,Phase 2,Phase 1
47 Immunologic Factors Phase 3,Phase 2,Phase 1,Not Applicable
48 Antirheumatic Agents Phase 3,Phase 2
49 Immunoglobulins Phase 3,Phase 2,Phase 1
50 Antineoplastic Agents, Immunological Phase 3,Phase 2

Interventional clinical trials:

(show top 50) (show all 128)
# Name Status NCT ID Phase Drugs
1 Sodium Oxybate in Patients With Chronic Fatigue Syndrome. Unknown status NCT01584934 Phase 4 Sodium oxybate;Placebo
2 Nasal Continuous Positive Airway Pressure (CPAP) in Chronic Fatigue and Sleep-disordered Breathing Unknown status NCT01368718 Phase 4
3 The Immune and Clinical Impacts of Vitamin D in Patients With Chronic Musculo-skeletal Pain Unknown status NCT01417923 Phase 4 vitamin D
4 SWS And Daytime Functioning in Chronic FatiguE Syndrome (SAFFE) Completed NCT02055898 Phase 4 Sodium Oxybate
5 Efficacy and Safety of Lisdexamfetamine Dimesylate in Adults With Chronic Fatigue Syndrome Completed NCT01071044 Phase 4 Lisdexamfetamine Dimesylate;Placebo "30, 50 or 70 mg"
6 Use of Sildenafil (Viagra) to Alter Fatigue, Functional Status and Impaired Cerebral Blood Flow in Patients With CFS Completed NCT00598585 Phase 4 Sildenafil (Viagra);Placebo
7 Giardia Induced Fatigue and Functional Gastrointestinal Diseases Completed NCT00860236 Phase 4
8 A Double Blind Randomised Placebo-controlled Trial to Assess the Role of Iron Repletion in Glucose Homeostasis. Recruiting NCT03191201 Phase 4 Ferric Carboxymaltose;0.9% sodium chloride solution
9 Use of Xyrem to Improve Sleep in Chronic Fatigue Syndrome Terminated NCT00498485 Phase 4 Placebo;Sodium Oxybate
10 B-lymphocyte Depletion Using Rituximab in Chronic Fatigue Syndrome/ Myalgic Encephalopathy (CFS/ME). A Randomized Phase-III Study. Unknown status NCT02229942 Phase 3 Rituximab;Placebo
11 Clinical Trial to Evaluate the Effectiveness of Acupuncture as a Treatment in Patients Diagnosed With CFS. Unknown status NCT01907711 Phase 2, Phase 3
12 Efficacy and Safety of Fermented Velvet Antler Extract on Fatigue Recovery After Exercise Unknown status NCT01689467 Phase 2, Phase 3
13 Cytokine Inhibition in Chronic Fatigue Syndrome Patients Completed NCT02108210 Phase 2, Phase 3 Anakinra;Placebo
14 Drug Intervention in Chronic Fatigue Syndrome Completed NCT00848692 Phase 2, Phase 3 Rituximab;Saline (NaCl 0,9 %) (placebo)
15 The Study of the Safety and Efficacy of Ampligen in Chronic Fatigue Syndrome Completed NCT00215800 Phase 3 Ampligen
16 Double Blind Trial of Duloxetine in Chronic Fatigue Syndrome Completed NCT00375973 Phase 2, Phase 3 Duloxetine;Placebo
17 Investigator Initiated Clinical Study to Explore the Efficacy and Safety of Human Placenta Hydrolysate in the Chronic Fatigue Patients Completed NCT01742013 Phase 3 GCJBP Laennec Inj.;Placebo
18 Clinical Trial to Measure the Maximun HR After ReConnect ® Supplementation vs. Placebo in CFS. Completed NCT02063126 Phase 2, Phase 3
19 Exercise and Behavioral Therapy Trial (EBT). Completed NCT00007748 Phase 3
20 Pilot, Opened, Randomized Clinical Trial to Assess the Efficacy of Duloxetine in the Treatment of Fibromialgy in Patients With Infection by HIV 1+ Completed NCT00552682 Phase 3 Duloxetine 60 mg, QD
21 The Exercise Response to Pharmacologic Cholinergic Stimulation in Preload Failure Enrolling by invitation NCT03674541 Phase 3 Pyridostigmine
22 Complementary Treatment of PG2 to Improve Clinical Benefit Response and Quality of Life in Fatigue Terminated NCT00518869 Phase 2, Phase 3 PG2
23 High-tech Acupuncture for Treatment of Chronic Fatigue Syndrome Unknown status NCT02924831 Phase 2
24 The Synergy Trial: Methylphenidate Plus a CFS-Specific Nutrient Formula as a Treatment for Chronic Fatigue Syndrome Unknown status NCT01966276 Phase 2 Methyl-P plus Nutrient Formula;Methyl-P plus Nutrient matched placebos
25 Treatment of Chronic Fatigue Syndrome (CFS) With Iodinated Activated Charcoal (IodoCarb®) Unknown status NCT01793415 Phase 1, Phase 2 IodoCarb (r)
26 Cyclophosphamide in Myalgic Encephalopathy/ Chronic Fatigue Syndrome (ME/CFS) Unknown status NCT02444091 Phase 2 Cyclophosphamide
27 Valganciclovir (Valcyte) for Chronic Fatigue Syndrome Patients Who Have Elevated Antibody Titers Against Human Herpes Virus 6 (HHV-6)and Epstein-Barr Virus (EBV) Unknown status NCT00478465 Phase 1, Phase 2 valganciclovir
28 Behavioral Insomnia Therapy With Chronic Fatigue Syndrome Completed NCT00540254 Phase 1, Phase 2
29 Pacing Activity Self-management for Patients With Chronic Fatigue Syndrome Completed NCT01512342 Phase 2
30 B-cell Depletion Using the Monoclonal Anti-CD20 Antibody Rituximab in Chronic Fatigue Syndrome Completed NCT01156909 Phase 2 Rituximab
31 The Norwegian Study of Chronic Fatigue Syndrome in Adolescents: Pathophysiology and Intervention Trial Completed NCT01040429 Phase 2 Clonidine;Lactose capsula
32 Acupressure for Post-Treatment Cancer Fatigue Completed NCT00959998 Phase 2
33 Transcranial Magnetic Stimulation for Treating Women With Chronic Widespread Pain Completed NCT00524420 Phase 2
34 Treatment Study of Carnosine Versus Placebo in Gulf War Illness (GWI) Completed NCT00810368 Phase 2 Carnosine;Placebo
35 Clinical Trial to Investigate CT38 in the Treatment of Myalgic Encephalomyelitis / Chronic Fatigue Syndrome Recruiting NCT03613129 Phase 1, Phase 2 CT38
36 The Comeback Study Recruiting NCT03691987 Phase 2
37 Creatine Supplementation in Chronic Fatigue Syndrome Active, not recruiting NCT02374112 Phase 2
38 Vestibulodynia: Understanding Pathophysiology and Determining Appropriate Treatments Not yet recruiting NCT03844412 Phase 2 5% lidocaine/5 mg/ml estradiol compound cream;Nortriptyline;Placebo cream;Placebo pill
39 Tumor Necrosis Factor-alpha Inhibition Using Etanercept in Chronic Fatigue Syndrome Terminated NCT01730495 Phase 2 Etanercept
40 B-cell Depletion Using the Monoclonal Anti-CD20 Antibody Rituximab in Very Severe Chronic Fatigue Syndrome Terminated NCT01156922 Phase 2 Rituximab
41 Study To Assess The Clinical Benefit Of Droxidopa In Subjects With Chronic Fatigue Syndrome Terminated NCT00977171 Phase 2 Droxidopa
42 Chronic Fatigue Syndrome: A Presumptive Mitochondrial Disorder Withdrawn NCT01471652 Phase 2 Nutraceutical supplements;Placebo
43 Autonomic Nervous System and Chronic Fatigue Syndrome Completed NCT00580619 Phase 1 L-NMMA trimethaphan;methyldopa
44 A Study to Investigate the Safety, Tolerability, Pharmacokinetics and Efficacy of BC 007 in Healthy Subjects Completed NCT02955420 Phase 1 BC 007;NaCl 0.9 %
45 Assessment of Neuroinflammation in Central Inflammatory Disorders Using [F-18]DPA-714. Recruiting NCT03759522 Phase 1 DPA-714 PET/MRI
46 Reducing Orthostatic Intolerance With Oral Rehydration in Myalgic Encephalomyelitis/Chronic Fatigue Syndrome Patients Active, not recruiting NCT02854683 Phase 1 Normal Saline
47 Tracking Peripheral Immune Cell Infiltration of the Brain in Central Inflammatory Disorders Using [Zr-89]Oxinate-4-labeled Leukocytes. Not yet recruiting NCT03807973 Phase 1
48 Observational Research on Use of Immunoprop Supplement in Chronic Fatigue Syndrome Unknown status NCT01893619
49 Acupuncture for the Sleep Disorder of Chronic Fatigue Syndrome Unknown status NCT01534130 Not Applicable
50 Thunder-Fire Moxibustion Therapy for Chronic Fatigue Syndrome on Shenque Acupoint: a Randomized Controlled Trial Unknown status NCT02964533 Not Applicable

Search NIH Clinical Center for Chronic Fatigue Syndrome

Inferred drug relations via UMLS 74 / NDF-RT 52 :


Cochrane evidence based reviews: fatigue syndrome, chronic

Genetic Tests for Chronic Fatigue Syndrome

Anatomical Context for Chronic Fatigue Syndrome

MalaCards organs/tissues related to Chronic Fatigue Syndrome:

42
Testes, Brain, Pituitary, Heart, Prostate, Lymph Node, B Cells

Publications for Chronic Fatigue Syndrome

Articles related to Chronic Fatigue Syndrome:

(show top 50) (show all 3207)
# Title Authors Year
1
Internet-Based Cognitive Behavioral Therapy in Stepped Care for Chronic Fatigue Syndrome: Randomized Noninferiority Trial. ( 30869642 )
2019
2
Diagnostic sensitivity of 2-day cardiopulmonary exercise testing in Myalgic Encephalomyelitis/Chronic Fatigue Syndrome. ( 30871578 )
2019
3
The PACE trial of treatments for chronic fatigue syndrome: a response to WILSHIRE et al. ( 30871632 )
2019
4
Pharmaceutical Interventions in Chronic Fatigue Syndrome: A Literature-based Commentary. ( 30871727 )
2019
5
Cognitive and behavioural responses to symptoms in adolescents with chronic fatigue syndrome: A case-control study nested within a cohort. ( 30873864 )
2019
6
Artificial intelligence based discovery of the association between depression and chronic fatigue syndrome. ( 30877861 )
2019
7
Impact of Polypharmacy on Candidate Biomarker miRNomes for the Diagnosis of Fibromyalgia and Myalgic Encephalomyelitis/Chronic Fatigue Syndrome: Striking Back on Treatments. ( 30889846 )
2019
8
Decreased Expression of the CD57 Molecule in T Lymphocytes of Patients with Chronic Fatigue Syndrome. ( 30895436 )
2019
9
Acceptance and identity change: An interpretative phenomenological analysis of carers' experiences in myalgic encephalopathy/chronic fatigue syndrome. ( 30895822 )
2019
10
Network structure underpinning (dys)homeostasis in chronic fatigue syndrome; Preliminary findings. ( 30908516 )
2019
11
Epigenetic Components of Myalgic Encephalomyelitis/Chronic Fatigue Syndrome Uncover Potential Transposable Element Activation. ( 30910331 )
2019
12
Corrigendum: Unperturbed Cytotoxic Lymphocyte Phenotype and Function in Myalgic Encephalomyelitis/Chronic Fatigue Syndrome Patients. ( 30915066 )
2019
13
Fibromyalgia, Chronic Fatigue Syndrome, and Multiple Chemical Sensitivity: Illness Experiences. ( 30917692 )
2019
14
Epstein-Barr Virus Induced Gene-2 Upregulation Identifies a Particular Subtype of Chronic Fatigue Syndrome/Myalgic Encephalomyelitis. ( 30918887 )
2019
15
Cognitive-behavorial and graded exercise therapies for chronic fatigue (syndrome) are associated with lower levels of work/school attendance. ( 30924061 )
2019
16
Comments on Chronic Fatigue Syndrome. ( 30926194 )
2019
17
Hyperactivation of proprioceptors induces microglia-mediated long-lasting pain in a rat model of chronic fatigue syndrome. ( 30927920 )
2019
18
Leveraging Prior Knowledge of Endocrine Immune Regulation in the Therapeutically Relevant Phenotyping of Women With Chronic Fatigue Syndrome. ( 30929860 )
2019
19
Rituximab for Patients With Myalgic Encephalomyelitis/Chronic Fatigue Syndrome. ( 30934061 )
2019
20
Myalgic Encephalomyelitis/Chronic Fatigue Syndrome: Trial Fails to Confirm Earlier Observations of Rituximab's Effectiveness. ( 30934063 )
2019
21
B-Lymphocyte Depletion in Patients With Myalgic Encephalomyelitis/Chronic Fatigue Syndrome: A Randomized, Double-Blind, Placebo-Controlled Trial. ( 30934066 )
2019
22
A Timely Multidisciplinary Update on Myalgic Encephalomyelitis/Chronic Fatigue Syndrome. ( 30940402 )
2019
23
Depressive symptoms in adolescents with chronic fatigue syndrome (CFS): Are rates higher than in controls and do depressive symptoms affect outcome? ( 30945566 )
2019
24
Varied Presentation of Myalgic Encephalomyelitis/Chronic Fatigue Syndrome and the Needs for Classification and Clinician Education: A Case Series. ( 30948154 )
2019
25
Response to Commentary: 'Myalgic Encephalomyelitis, Chronic Fatigue Syndrome, and Chronic Fatigue: Three Distinct Entities Requiring Complete Different Approaches'. ( 30955109 )
2019
26
Chronotropic Intolerance: An Overlooked Determinant of Symptoms and Activity Limitation in Myalgic Encephalomyelitis/Chronic Fatigue Syndrome? ( 30968005 )
2019
27
Evidence of Clinical Pathology Abnormalities in People with Myalgic Encephalomyelitis/Chronic Fatigue Syndrome (ME/CFS) from an Analytic Cross-Sectional Study. ( 30974900 )
2019
28
Corrigendum: Neuroinflammation and Cytokines in Myalgic Encephalomyelitis/Chronic Fatigue Syndrome (ME/CFS): A Critical Review of Research Methods. ( 31001197 )
2019
29
Letter to the Editor: Myalgic Encephalomyelitis and Chronic Fatigue Syndrome: Definitions, Similarities, and Differences. ( 31003734 )
2019
30
Prediction of long-term outcome after cognitive behavioral therapy for chronic fatigue syndrome. ( 31006534 )
2019
31
Validation of impaired Transient Receptor Potential Melastatin 3 ion channel activity in natural killer cells from Chronic Fatigue Syndrome/ Myalgic Encephalomyelitis patients. ( 31014226 )
2019
32
In Search of Effective Treatments for Myalgic Encephalomyelitis/Chronic Fatigue Syndrome. ( 31030992 )
2019
33
A nanoelectronics-blood-based diagnostic biomarker for myalgic encephalomyelitis/chronic fatigue syndrome (ME/CFS). ( 31036648 )
2019
34
Epstein-Barr Virus dUTPase Induces Neuroinflammatory Mediators: Implications for Myalgic Encephalomyelitis/Chronic Fatigue Syndrome. ( 31040055 )
2019
35
The 'cognitive behavioural model' of chronic fatigue syndrome: Critique of a flawed model. ( 31041108 )
2019
36
Child and adolescent chronic fatigue syndrome/myalgic encephalomyelitis: where are we now? ( 31045885 )
2019
37
Searching for Serum Antibodies to Neuronal Proteins in Patients With Myalgic Encephalopathy/Chronic Fatigue Syndrome. ( 31053295 )
2019
38
Cellular Immune Function in Myalgic Encephalomyelitis/Chronic Fatigue Syndrome (ME/CFS). ( 31057538 )
2019
39
Myalgia and chronic fatigue syndrome following immunization: macrophagic myofasciitis and animal studies support linkage to aluminum adjuvant persistency and diffusion in the immune system. ( 31059838 )
2019
40
Assessment of the scientific rigour of randomized controlled trials on the effectiveness of cognitive behavioural therapy and graded exercise therapy for patients with myalgic encephalomyelitis/chronic fatigue syndrome: A systematic review. ( 31072121 )
2019
41
Myalgic Encephalomyelitis, Chronic Fatigue Syndrome, and Chronic Fatigue: Three Distinct Entities Requiring Complete Different Approaches. ( 31073713 )
2019
42
Cognitive behavioural therapy for myalgic encephalomyelitis/chronic fatigue syndrome is not effective. Re-analysis of a Cochrane review. ( 31080632 )
2019
43
A possible role for mitochondrial-derived peptides humanin and MOTS-c in patients with Q fever fatigue syndrome and chronic fatigue syndrome. ( 31088495 )
2019
44
Increased risk of chronic fatigue syndrome following psoriasis: a nationwide population-based cohort study. ( 31088562 )
2019
45
Resting-state functional connectivity, cognition, and fatigue in response to cognitive exertion: a novel study in adolescents with chronic fatigue syndrome. ( 31102168 )
2019
46
Letter to the Editor (March 3, 2019) concerning the paper "The relationship between chronic fatigue syndrome, burnout, job satisfaction, social support and age among academics at a tertiary institution". ( 31112140 )
2019
47
Authors' response (April 8, 2019) concerning the paper "The relationship between chronic fatigue syndrome, burnout, job satisfaction, social support and age among academics at a tertiary institution". ( 31112141 )
2019
48
Home-based family focused rehabilitation for adolescents with severe Chronic Fatigue Syndrome. ( 30114945 )
2019
49
Chronic fatigue syndrome and the somatic expression of emotional distress: Applying the concept of illusory mental health to address the controversy. ( 30152867 )
2019
50
A new approach to find biomarkers in chronic fatigue syndrome/myalgic encephalomyelitis (CFS/ME) by single-cell Raman micro-spectroscopy. ( 30207334 )
2019

Variations for Chronic Fatigue Syndrome

ClinVar genetic disease variations for Chronic Fatigue Syndrome:

6
# Gene Variation Type Significance SNP ID Assembly Location
1 MT-CO3 NC_012920.1: m.9355A> T single nucleotide variant Uncertain significance rs1556423663 GRCh37 Chromosome MT, 9355: 9355
2 MT-CO3 NC_012920.1: m.9355A> T single nucleotide variant Uncertain significance rs1556423663 GRCh38 Chromosome MT, 9355: 9355

Expression for Chronic Fatigue Syndrome

Search GEO for disease gene expression data for Chronic Fatigue Syndrome.

Pathways for Chronic Fatigue Syndrome

Pathways related to Chronic Fatigue Syndrome according to GeneCards Suite gene sharing:

(show top 50) (show all 71)
# Super pathways Score Top Affiliating Genes
1
Show member pathways
14.08 CXCL8 EIF2AK2 IL10 IL1B IL2 IL6
2
Show member pathways
13.6 CXCL8 EIF2AK2 IGF1 IL10 IL1B IL2
3
Show member pathways
13.46 CXCL8 IGF1 IL10 IL1B IL2 IL6
4
Show member pathways
13.42 CXCL8 EIF2AK2 IL10 IL1B IL2 IL6
5
Show member pathways
13.36 CXCL8 IGF1 IL10 IL1B IL2 IL6
6
Show member pathways
13.18 CXCL8 IL10 IL1B IL2 IL6 RNASEL
7
Show member pathways
13 CXCL8 EIF2AK2 IL1B IL6 TGFB1 TNF
8
Show member pathways
12.96 CXCL8 IL10 IL1B IL2 IL6 TGFB1
9 12.87 CXCL8 IGF1 IL2 IL6 TGFB1
10
Show member pathways
12.81 EIF2AK2 IGF1 IL1B IL2 IL6 TGFB1
11
Show member pathways
12.68 IL10 IL1B IL2 IL6 TGFB1 TNF
12
Show member pathways
12.68 EIF2AK2 IL10 IL1B IL2 IL6 TNF
13
Show member pathways
12.67 IL10 IL1B IL2 IL6 TGFB1 TNF
14 12.62 IL10 IL1B IL2 RNASEL TNF
15 12.38 IL2 IL6 TGFB1 TNF
16
Show member pathways
12.37 IL1B IL2 IL6 TNF
17
Show member pathways
12.37 CXCL8 IL1B IL6 TNF
19
Show member pathways
12.34 CXCL8 IL1B IL6 TNF
20 12.33 IL10 IL1B IL6 TGFB1 TNF
21
Show member pathways
12.31 IL10 IL1B IL2 IL6 TNF
22
Show member pathways
12.3 IL10 IL1B TGFB1 TNF
23
Show member pathways
12.27 CXCL8 IL1B IL6 TNF
24
Show member pathways
12.27 IGF1 IL6 TGFB1 TNF
25
Show member pathways
12.24 CXCL8 IL1B IL6 TNF
26
Show member pathways
12.23 CXCL8 IGF1 IL10 IL1B IL2 IL6
27 12.17 IGF1 IL6 NR3C1 TGFB1 TNF
28
Show member pathways
12.17 IL10 IL1B IL2 IL6 TGFB1 TNF
29
Show member pathways
12.15 IGF1 IL10 IL6 TGFB1
30
Show member pathways
12.13 CXCL8 EIF2AK2 IGF1 IL10 IL1B IL2
31 12.1 CXCL8 IL1B IL2 IL6 TGFB1 TNF
32 12.06 IL10 IL2 IL6 TNF
33 12.06 HTR1A MAOA SLC6A4 TPH2
34 12.03 CXCL8 IL1B IL6 TGFB1 TNF
35 12 CXCL8 IGF1 IL1B IL6 RNASEL TGFB1
36 11.99 CRH CXCL8 IL2 POMC TGFB1
37 11.97 CXCL8 IL1B IL6 TGFB1 TNF
38 11.94 CXCL8 IL10 IL1B IL6 TGFB1 TNF
39 11.91 CXCL8 IL2 IL6 NR3C1 POMC
40 11.89 IL10 IL1B IL2 TNF
41 11.86 CXCL8 IL10 IL1B IL6 TNF
42 11.85 CXCL8 IL1B IL6
43 11.8 IL10 IL1B IL2 IL6 TGFB1 TNF
44
Show member pathways
11.79 CXCL8 IL2 TNF
45 11.71 CXCL8 IGF1 IL1B IL6 TGFB1 TNF
46 11.7 CXCL8 IL1B IL6 TNF
47
Show member pathways
11.68 CXCL8 IL1B IL2 IL6 NR3C1 TNF
48 11.65 CXCL8 IL10 IL1B IL6 TNF
49 11.65 IGF1 IL10 IL1B IL2 IL6 TGFB1
50 11.64 IL1B IL2 TGFB1 TNF

GO Terms for Chronic Fatigue Syndrome

Cellular components related to Chronic Fatigue Syndrome according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 extracellular region GO:0005576 9.65 CRH CXCL8 IGF1 IL10 IL1B IL2
2 extracellular space GO:0005615 9.32 CRH CXCL8 IGF1 IL10 IL1B IL2

Biological processes related to Chronic Fatigue Syndrome according to GeneCards Suite gene sharing:

(show top 50) (show all 60)
# Name GO ID Score Top Affiliating Genes
1 positive regulation of gene expression GO:0010628 9.98 CRH IGF1 IL1B IL6 SLC6A4 TGFB1
2 positive regulation of transcription by RNA polymerase II GO:0045944 9.96 IGF1 IL10 IL1B IL2 IL6 NR3C1
3 positive regulation of protein phosphorylation GO:0001934 9.93 CRH IL1B IL2 TGFB1 TNF
4 positive regulation of DNA-binding transcription factor activity GO:0051091 9.91 IL10 IL1B IL6 TNF
5 cellular response to lipopolysaccharide GO:0071222 9.91 CXCL8 IL10 IL1B IL6 TNF
6 positive regulation of peptidyl-serine phosphorylation GO:0033138 9.89 IL6 TGFB1 TNF
7 cellular response to organic cyclic compound GO:0071407 9.88 IL1B TGFB1 TNF
8 positive regulation of tyrosine phosphorylation of STAT protein GO:0042531 9.88 IGF1 IL2 IL6
9 response to estrogen GO:0043627 9.88 COMT CRH TPH2
10 response to organic substance GO:0010033 9.88 IL10 SLC6A4 TGFB1 TNF
11 response to drug GO:0042493 9.88 COMT CRH IL10 SLC6A4 TGFB1
12 positive regulation of T cell proliferation GO:0042102 9.87 IL1B IL2 IL6
13 inflammatory response GO:0006954 9.87 CRH CXCL8 IL10 IL1B IL6 TGFB1
14 positive regulation of interleukin-6 production GO:0032755 9.86 IL1B IL6 TNF
15 positive regulation of smooth muscle cell proliferation GO:0048661 9.86 IGF1 IL6 TNF
16 positive regulation of NIK/NF-kappaB signaling GO:1901224 9.85 EIF2AK2 IL1B TNF
17 negative regulation of fat cell differentiation GO:0045599 9.85 IL6 TGFB1 TNF
18 positive regulation of vascular smooth muscle cell proliferation GO:1904707 9.85 IGF1 IL10 TNF
19 positive regulation of NF-kappaB transcription factor activity GO:0051092 9.85 EIF2AK2 IL1B IL6 TGFB1 TNF
20 positive regulation of interferon-gamma production GO:0032729 9.83 IL1B IL2 TNF
21 negative regulation of viral genome replication GO:0045071 9.82 EIF2AK2 RNASEL TNF
22 lipopolysaccharide-mediated signaling pathway GO:0031663 9.82 IL1B TGFB1 TNF
23 negative regulation of mitotic cell cycle GO:0045930 9.81 IL10 TGFB1 TNF
24 cellular response to dexamethasone stimulus GO:0071549 9.79 CRH NR3C1 TGFB1
25 negative regulation of neurogenesis GO:0050768 9.77 IL1B IL6 TNF
26 cell activation GO:0001775 9.73 IGF1 TGFB1
27 positive regulation of chemokine production GO:0032722 9.73 EIF2AK2 IL6 TNF
28 positive regulation of immunoglobulin secretion GO:0051024 9.72 IL2 IL6
29 positive regulation of regulatory T cell differentiation GO:0045591 9.72 IL2 TGFB1
30 response to molecule of bacterial origin GO:0002237 9.72 CXCL8 IL10
31 positive regulation of glial cell proliferation GO:0060252 9.72 IL1B IL6 TNF
32 catecholamine metabolic process GO:0006584 9.71 COMT MAOA
33 neurotransmitter catabolic process GO:0042135 9.71 COMT MAOA
34 negative regulation of lipid storage GO:0010888 9.71 IL6 TNF
35 protein kinase B signaling GO:0043491 9.71 IGF1 IL1B TGFB1 TNF
36 dopamine catabolic process GO:0042420 9.7 COMT MAOA
37 endothelial cell apoptotic process GO:0072577 9.7 IL10 TNF
38 positive regulation of heterotypic cell-cell adhesion GO:0034116 9.7 IL10 IL1B TNF
39 positive regulation of chemokine biosynthetic process GO:0045080 9.69 IL1B TNF
40 regulation of establishment of endothelial barrier GO:1903140 9.68 IL1B TNF
41 negative regulation of cytokine secretion involved in immune response GO:0002740 9.68 IL10 TNF
42 positive regulation of fever generation GO:0031622 9.67 IL1B TNF
43 sequestering of triglyceride GO:0030730 9.65 IL1B TNF
44 positive regulation of calcidiol 1-monooxygenase activity GO:0060559 9.63 IL1B TNF
45 positive regulation of mononuclear cell migration GO:0071677 9.63 TGFB1 TNF
46 receptor biosynthetic process GO:0032800 9.62 IL10 TNF
47 regulation of signaling receptor activity GO:0010469 9.61 CXCL8 IGF1 IL10 IL1B IL2 IL6
48 regulation of serotonin secretion GO:0014062 9.6 CRH HTR1A
49 response to immobilization stress GO:0035902 9.58 CRH TGFB1
50 positive regulation of neuroinflammatory response GO:0150078 9.54 IL1B IL6 TNF

Molecular functions related to Chronic Fatigue Syndrome according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 growth factor activity GO:0008083 9.35 IGF1 IL10 IL2 IL6 TGFB1
2 cytokine activity GO:0005125 9.17 CXCL8 IL10 IL1B IL2 IL6 TGFB1
3 serotonin binding GO:0051378 9.16 HTR1A SLC6A4

Sources for Chronic Fatigue Syndrome

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
20 FMA
29 GO
30 GTR
31 HGMD
32 HMDB
33 HPO
34 ICD10
35 ICD10 via Orphanet
36 ICD9CM
37 IUPHAR
38 KEGG
39 LifeMap
41 LOVD
43 MedGen
45 MeSH
46 MESH via Orphanet
47 MGI
50 NCI
51 NCIt
52 NDF-RT
55 NINDS
56 Novoseek
58 OMIM
59 OMIM via Orphanet
63 PubMed
65 QIAGEN
70 SNOMED-CT via HPO
71 SNOMED-CT via Orphanet
72 TGDB
73 Tocris
74 UMLS
75 UMLS via Orphanet
Content
Loading form....